Tumor Stem Cell Assay

• 

  Subject Areas on Research

  • ATM Paradoxically Promotes Oncogenic Transformation via Transcriptional Reprogramming. 
  • Altered growth of a human neuroendocrine carcinoma line after transfection of a major histocompatibility complex class I gene. 
  • Anchorage-independent cell growth signature identifies tumors with metastatic potential. 
  • Ataxia-telangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NF-κB pathway. 
  • BP1, a new homeobox gene, is frequently expressed in acute leukemias. 
  • Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. 
  • Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. 
  • Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. 
  • Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement. 
  • Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines. 
  • Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione. 
  • Differentiation of normal marrow and HL60 cells induced by antithymocyte globulin. 
  • Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. 
  • Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. 
  • Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin. 
  • Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. 
  • Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells. 
  • Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. 
  • Experimental chemotherapy of human medulloblastoma with classical alkylators. 
  • Fabrication and testing of a device capable of reducing the incidence of ventricular shunt promoted metastasis. 
  • HEPSIN inhibits cell growth/invasion in prostate cancer cells. 
  • Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. 
  • In vitro and in vivo investigations for the development of cytostatic methylhydrazones. 
  • Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. 
  • Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance. 
  • Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. 
  • Optimization and characterization of the capillary human tumor clonogenic cell assay. 
  • Potential antiglioma activity of 9-hydroxy-2-N-methylellipticine as determined by pharmacological and human tumor clonogenic cell studies. 
  • RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence. 
  • Relationship between histopathology and in vitro clonogenicity in breast cancer. 
  • Schedule and concentration-dependent induction of apoptosis in leukemia cells by nitric oxide. 
  • Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1. 
  • Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins. 
  • The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. 
  • The accelerated repopulation of a murine fibrosarcoma, FSA-II, during the fractionated irradiation and the linear-quadratic model. 
  • Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. 
  • Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. 
  • Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. 
  • Vitamin K in the treatment of cancer. 
  • Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation.